Hospitalizations for heart failure in the United States--a sign of hope.
暂无分享,去创建一个
[1] G. Filippatos,et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.
[2] Harlan M Krumholz,et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.
[3] M. Gheorghiade,et al. Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. , 2011, JAMA.
[4] K. Swedberg,et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. , 2011, American heart journal.
[5] Adrian F Hernandez,et al. Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[6] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[7] R. Bonow,et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. , 2010, Circulation.
[8] S. Normand,et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. , 2010, JAMA.
[9] P. Ponikowski,et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine , 2010, European journal of heart failure.
[10] C. O'connor,et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. , 2010, American heart journal.
[11] M. Gheorghiade,et al. The current and future management of acute heart failure syndromes. , 2010, European heart journal.
[12] A. Laupacis,et al. Early Deaths in Patients With Heart Failure Discharged From the Emergency Department: A Population-Based Analysis , 2010, Circulation. Heart failure.
[13] Sanjiv J Shah,et al. Heart failure with preserved ejection fraction: treat now by treating comorbidities. , 2008, JAMA.
[14] Nancy M Albert,et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. , 2007, JAMA.
[15] G. Filippatos,et al. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. , 2006, The American journal of medicine.
[16] Nancy M Albert,et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.
[17] Ali Ahmed,et al. Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.
[18] Harlan M Krumholz,et al. ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.
[19] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[20] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[21] S. Werns. Diuretic Strategies in Patients with Acute Decompensated Heart Failure , 2012 .
[22] B. Kozłowski. Summary of the article: Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. Engl J Med, 2011; 364: 797–805 , 2011 .
[23] T. Rywik. [Summary of the article: Zannad F, McMurray JJV, Krum H et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21]. , 2011, Kardiologia polska.
[24] W. Frishman,et al. Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure , 2007 .
[25] A. Germing. Effects of digoxin on morbidity and mortality in diastolic heart failure , 2006 .